Kangwei Century's Company Team

Kang has brought together a group of experts from various fields of biotechnology for the century. Some of them have many years of overseas study experience and some have successful entrepreneurial experience. They are not only proficient in professional technology, but also have rich management experience. More importantly, they have passion, ideals and a sense of responsibility, and they are trustworthy partners on your scientific research road.

Wang Chunxiang, executive director and general manager

received a bachelor's degree and a master's degree in biology from Peking University and a doctorate in pathology from UCLA. In 1999, he returned to China to work for Beijing Jinsaishi Biopharmaceutical Co., Ltd. and served as the head of the R&D project, mainly developing genetically engineered probiotics and protein drugs, and applying for two invention patents. In 22, he founded Beijing Tianwei Times Technology Co., Ltd. as executive director and general manager. Tianwei Times Company is mainly engaged in the research and development, production and sales of molecular biology products. Due to the standardized production process and strict quality control, the products of Tianwei Times have been well received by customers and recognized by the international giant Qiagen. In 25, he participated in the establishment of Tiangen Biochemical Technology (Beijing) Co., Ltd., a wholly-owned subsidiary of Qiagen in China, and became the first general manager. In 27, Beijing Kangwei Century Biotechnology Co., Ltd. was founded, and now he is the executive director and general manager, responsible for the overall operation and development of the company, determined to build Kangwei Century Company into an internationally influential biotechnology company in China, which will greatly promote life science research and human health.

Vice President Research and Development

Bachelor, Master and Doctor in Biology Department of Peking University. He has been engaged in the preparation and application of monoclonal antibodies and the molecular biology of hepatitis virus for a long time. He once worked in Peking University Institute of Hepatology, participated in the development of HBVPreS2 antigen/antibody diagnostic kit, and presided over the preparation of the only monoclonal antibody against HBV pres2 protein in China at that time. As the main participant, I participated in the development of hepatitis C diagnostic reagents and the formulation of standards in the Eighth Five-Year Plan and the Ninth Five-Year Plan of the Ministry of Health, and formulated the quality control standards for the first generation of hepatitis C diagnostic reagents in China. The project won the second prize of national scientific and technological progress, the first prize of the Ministry of Health and the first prize of Beijing scientific and technological progress. From 2 to 24, he conducted postdoctoral research in the Department of Molecular Biology of Dalhousie University in Canada and Wisconsin Medical College in the United States. After returning to China in 24, he worked in the Academy of Military Sciences and protein Group Research Center as a researcher, mainly engaged in the Qualcomm-quantity and large-scale antibody preparation and application research of monoclonal antibodies, and did a lot of research work on the improvement of hybridoma technology, and participated in the application for 2 national patents. Take on a national 973 project as the project leader. He joined Kangwei Century in May 28, and is now in charge of the R&D department of the company, leading the team to make unremitting efforts in the development of new products, the improvement of existing product quality and the continuous improvement of technical service level.

served as technical director of the military

received bachelor's, master's and doctor's degrees from West China University of Medical Sciences, the University of New South Wale in Australia and the University of Guelph in Canada. After returning to China in 24, he worked as a postdoctoral researcher in the Molecular Virus Laboratory of Shanghai Medical College of Fudan University. In 26, he was employed as an associate researcher at Fudan University. The research direction is the interaction between hepatitis B virus and host. In the meantime, he participated in key projects of Shanghai and National Natural Science Foundation. He has been engaged in research work related to pathogenic biology for a long time since the doctoral stage, and is proficient in microbiology, molecular biology, cell biology and other related experimental techniques. Published more than ten papers at home and abroad. In 27, he served as the director of biological laboratory in Shanghai Gus Biomedical Co., Ltd., engaged in the research and development of new drugs. During this period, a fully functional laboratory of cell biology and molecular biology was established. A reliable and sensitive medium flux screening platform was established for GPCR target, and a number of candidate drugs with specific biological activities were screened out. He joined Kangwei Century in 21, and now he is responsible for the company's technical support, technical services and research and development of molecular biology products.